Idiopathic hypertrophic pachymeningitis: A case report and review of the literature

Anahita zoghi1, Navid Rahimi2*, Shervin shokouhi3 and Ehsan sakhaee4

1Assistant Professor of Neurology Shahid Beheshti University of Medical Science Loghman Hakim Hospital, Iran
2MD Rheumatology Fellowship Iran University of Medical Science (IUMS) Hazrat Rasool General Hospital, Iran
3Associate Professor of Infectious Disease Shahid Beheshti University of Medical Science Loghman Hakim Hospital, Iran
4MD Neurology Resident Shahid Beheshti University of Medical Science Loghman Hakim Hospital, Iran
*Corresponding email: dr.navid57@gmail.com

ABSTRACT

We report the treatment and follow-up, including magnetic resonance imaging (MRI) of a patient with idiopathic hypertrophic pachymeningitis and review the literature published in 21th century, with emphasis on the management and clinical outcomes of this rare disorder. Hypertrophic pachymeningitis is extremely rare. It is a fibrosing inflammatory process which involves the dura mater. Numerous pathological entities produce thickening of the pachymeninges. Thus, idiopathic hypertrophic pachymeningitis is diagnosed by exclusion. We present a case of patient with idiopathic hypertrophic pachymeningitis who had varied clinical presentation. Imaging studies revealed diffuse thickening of the pachymeninges.

Keywords: Pachymeningitis, Hypertrophic, Review,

INTRODUCTION

Idiopathic hypertrophic pachymeningitis (IHP) is a chronic progressive diffuse inflammatory fibrosis of the dura mater, leading to its diffuse thickening. This rare disorder is usually found intracranially though spinal forms have also been reported [1]. The first was described by Charcot and Joffroy as a “process in which the neighboring leptomeninges always suffers as well becoming opaque and thick, and further united to the dura and cord”. MRI is the examination of choice in preliminary diagnosis of IHP. Histopathological examination of a biopsy specimen of the dura mater would finally confirm the diagnosis [2]. The following presents a patient with IHP and discusses the clinical features, radiological and pathological findings of this rare disorder.

CASE PRESENTATION

A 64 year old man (from Amol, Iran), who had a progressive daily headache since October 2014 for a few minutes in the morning and afternoon every day. His headache was sharp on bifrontal and sometimes pulsatile without nausea and vomiting, photophobia, phonophobia or osmophobia with improvement in recumbent position. He developed bilateral facial numbness since April 2015 and gradually bilateral blurred vision. Speech disorder was added to his symptoms since July 2015 and he was hospitalized for severe exacerbation of his headache on August 2015. At the first clinical examination, he had dysarthria due to left hypoglossal nerve palsy, hyposthesia in bilateral V1 cranial nerves territory and bilateral visual acuity of 7/10. To elucidate these findings, MRI was performed, that showed extensive thickening and enhancement of the dura (Fig. 1). The erythrocyte sedimentation rate (ESR) was 80 mm/h (normal 1-20 mm/h), C-reactive protein (CRP) was 51mg/l but other blood investigations include complete blood count (CBC), renal function test (RFT), liver function test (LFT), serum biochemistry, cerebrospinal fluid (CSF), and studies for ADA, ACE, TB PCR, Aspergillus PCR, Cryptococcus PCR, wright and cytology (three time) all were normal. CSF protein and CSF WBC number were respectively 80 mg/dl and 81 (PMN 30% & monocyte 70%) with normal CSF sugar and CSF pressure. ANA, ds-DNA, c-ANCA, p-ANCA, serum Ig G4 level,
SSA-Ro, SSB-La, VDRL, ACLA, anti phospholipid antibody, lupus anticoagulant, wright, 2ME were within normal limits or negative. Blood borne virus screen including HIV antibody, HBsAg, HCV antibody all were negative too. PPD test and chest CT scan were normal. After all of these evaluations were done, biopsy of the thickened pachymeninge revealed chronic inflammatory cell infiltration with granulomatous reaction without any evidences of the fungus, acid fast bacilli or malignancy. (Fig 2).

Figure 1: Brain MRI shows thickening and enhancement of pachymeninge in T1 WI with contrast

Fig. 2- Histopathological features of a specimen obtained during dural biopsy. A)view showing diffusely thickened, fibrotic dura and marked infiltration by inflammatory cells, with granulomatus reaction (circle) (hematoxylin and eosin; original magnification, ×40). B) higher-magnification view showing lymphocytes, plasma cells, histiocytes and giant PMN (arrow) (hematoxylin and eosin; original magnification, ×100)
After treatment with methylprednisolone 5 gr divided doses in five days, his headache subsided. Treatment continued with 50 mg/day prednisolone. His signs and symptoms except for dysarthria were improved and dural thickening decreased in follow up 4 months later (Fig 3).

Figure 3- Brain MRI shows a decrease in thickening of pachymeninge in T1 WI with contrast

DISCUSSION

Hypertrophic cranial pachymeningitis is a rare, idiopathic form of granulomatous pachymeningitis. These lesions typically cause progressive cranial nerve palsy, headache and cerebellar dysfunction. It occurs in all age groups but its peak incidence is in the sixth decade of life. Hypertrophic cranial pachymeningitis is best identified by MRI. The diagnosis is established by excluding all other granulomatous and infectious diseases [3]. A dural biopsy is essential to confirm the diagnosis. Pathological findings consist of thick fibrous dura often associated with chronic inflammatory cell infiltration specially lymphocytes and plasma cells [4].

Hypertrophic cranial pachymeningitis is initially responsive to steroid therapy, but in most cases it recurs or progresses despite the treatment. Surgical excision of granulomas is occasionally necessary to alleviate a mass effect [3]. Pachymeningitis is a term used to define the state in which there is localized or diffuse thickening of the dura mater, usually adjacent to an inflammatory focus. The causes of dural thickening include epidural abscess, rheumatoid arthritis, lymphoma, neurosyphilis, sarcoidosis, tuberculosis, and intracranial fibromatosis. IHP may extend to involve the skull base and adjacent tissues. Pathologically, there is diffuse thickening of the dura mater with considerable fibrosis, chronic inflammatory cells including plasma cells and lymphocytes are seen on microscopy. Generally, there is a elevation of the erythrocyte sedimentation rate, and cerebrospinal fluid studies reveal elevated levels of cells and protein [5, 6].

Hypertrophic pachymeningitis (HP) is divided into two types: IHP in which no identifiable cause is found; and secondary HP in which there is an identifiable coexisting cause. Therefore, IHP is a diagnosis of exclusion. In our patient, exhaustive attempts to identify the cause of the dura thickening were unsuccessful.

Clinical manifestations in the majority of patients are similar. The most common symptoms of cranial IHP are headache and cranial nerve palsy [7-9]. IHP may also manifest with chronic headache resembling migraine. Headache, attributed to focal dural inflammation is a universal symptom, and at times may be the only symptom for many years. Intraparenchymal involvement in IHP is rare [10]. The above-mentioned patient presented with headache and multiple cranial nerve involvement.
Dense fibrosis and inflammatory cell infiltration are common histopathological features of IHP [11-13], and in addition to these findings, vasculitis or granulomatous changes have also been reported in several cases [14, 15]. The present case had inflammatory changes in the dura, and as well as epitheloid cells and granulomatous Mikawa et al. subdivided IHP into two groups: first, those with inflammatory signs including fever, increased ESR, leukocytosis, and increased CRP (group P); and second, those without inflammatory signs (group N). They suggested that group P had worse prognosis than group N [16, 17]. Our patient had raised ESR and CRP, so he belongs to group P.

This patient had CSF pleocytosis and increased protein with normal intracranial pressure. Dural inflammation may play a main role in causing headache because in many cases no evidences of raised intracranial pressure are present [18].

MANAGEMENT

The Table 1 summarizes the methods of treatment and outcomes in the patients with hypertrophic pachymeningitis in which MRI or CT documentation were published in 21th century. Most of these patients were idiopathic. Given that management differs for the cranial (ICHP) and spinal (ISHP) forms, we separately address their managements here.

As illustrated in the Table, therapeutic strategies for ICHP include steroids, azathioprine, methotrexate, radiotherapy, surgery and observation. Early treatment is an important point in management of these patients because of its association with improved outcome in terms of neurological recovery [19]. Ventriculoperitoneal shunt and antiepileptic drugs may be needed for symptom therapy. Corticosteroids such as prednisolone could decrease the dural thickening as documented with MRI and resulted in dramatic reduction or even complete remission of symptoms in some patients. Patients may become steroid dependent. Surgical techniques and ventriculoperitoneal shunt have been used with variable success. An empirical treatment with antituberculous drugs may be warranted in selected patients.

<table>
<thead>
<tr>
<th>Author et al</th>
<th>Age</th>
<th>Sex</th>
<th>Description</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martin et al</td>
<td>20</td>
<td>F</td>
<td>Intracranial</td>
<td>Corticosteroids, Azathioprine</td>
<td>Improvement at 4 months, asymptomatic at 18 months</td>
</tr>
<tr>
<td>Lee et al</td>
<td>23</td>
<td>F</td>
<td>Intracranial</td>
<td>Corticosteroids, Azathioprine</td>
<td>Progression at 5 years</td>
</tr>
<tr>
<td>Riku et al</td>
<td>58</td>
<td>M</td>
<td>Intracranial</td>
<td>Corticosteroids, Azathioprine</td>
<td>Improvement with diminished tentorial enhancement at 16 months</td>
</tr>
<tr>
<td>Gollogly et al</td>
<td>73</td>
<td>M</td>
<td>Intracranial</td>
<td>Surgery</td>
<td>Improved</td>
</tr>
<tr>
<td>Lee et al</td>
<td>23</td>
<td>M</td>
<td>Intracranial</td>
<td>Corticosteroids</td>
<td>Asymptomatic at 3 years of follow-up</td>
</tr>
<tr>
<td>Kanzaki et al</td>
<td>70</td>
<td>F</td>
<td>Intracranial</td>
<td>Corticosteroids</td>
<td>Improved at 2 years</td>
</tr>
<tr>
<td>Rossi et al</td>
<td>48</td>
<td>F</td>
<td>Intracranial</td>
<td>Corticosteroids</td>
<td>Psychic symptoms unchanged</td>
</tr>
<tr>
<td>Terada et al</td>
<td>52</td>
<td>F</td>
<td>Intracranial</td>
<td>Corticosteroids, Azathioprine</td>
<td>Progression at 5 years</td>
</tr>
<tr>
<td>Terada et al</td>
<td>58</td>
<td>M</td>
<td>Intracranial</td>
<td>Corticosteroids, Azathioprine</td>
<td>Improvement with diminished tentorial enhancement at 16 months</td>
</tr>
<tr>
<td>Muthukumar et al</td>
<td>60</td>
<td>F</td>
<td>Intracranial</td>
<td>Corticosteroids</td>
<td>Neurologically stable 6 months, but recurrence</td>
</tr>
<tr>
<td>Pai et al</td>
<td>47</td>
<td>F</td>
<td>Spinal: T1T6</td>
<td>Laminectomy</td>
<td>Spontaneous temporary resolution of symptoms, recurrence after surgery</td>
</tr>
<tr>
<td>Kesavadas et al</td>
<td>49</td>
<td>F</td>
<td>Intracranial</td>
<td>Corticosteroids</td>
<td>Progression in symptoms at 10 years</td>
</tr>
<tr>
<td>Bruggemann et al</td>
<td>78</td>
<td>F</td>
<td>Intracranial</td>
<td>Corticosteroids</td>
<td>Resolved aphasia, persistent Headache after 6 months</td>
</tr>
<tr>
<td>van Toorn et al</td>
<td>10</td>
<td>M</td>
<td>Intracranial</td>
<td>Oral methotrexate</td>
<td>Recurrent after 21 months</td>
</tr>
<tr>
<td>Bosman et al</td>
<td>62</td>
<td>M</td>
<td>Intracranial</td>
<td>Oral Methotrexate</td>
<td>Improvement within the 6 weeks</td>
</tr>
<tr>
<td>Witoonpanich et al</td>
<td>60</td>
<td>F</td>
<td>Intracranial</td>
<td>Steroids, Azathioprine, Cyclophosphamide</td>
<td>Improvement at 7 months</td>
</tr>
<tr>
<td>Kesavadas et al</td>
<td>49</td>
<td>F</td>
<td>Intracranial</td>
<td>Corticosteroids, Azathioprine</td>
<td>Developed central scotoma and optic disc swelling of</td>
</tr>
</tbody>
</table>
In conclusion, although Idiopathic hypertrophic pachymeningitis (IHP) is a rare disorder, the clinical and radiological findings are characteristic. The most frequently encountered neurological manifestations include headache, cranial nerve palsy and enhanced thickened dura that can easily lead to a diagnosis. The diagnosis of IHP is based on MRI examination and histopathological assessment of dura mater biopsy specimen. The pathologic and laboratory data suggest a close association with granulomatous or connective tissue disease. Therefore, we postulate that IHP might be an autoimmune systemic inflammation, which is localized in the dura mater.
Acknowledgement

This study was supported by the Clinical Research Development Center of Loghman Hakim Hospital affiliated to Shahid Beheshti University of Medical Sciences, Tehran, Iran.

REFERENCES


[51] Che-Kuang Lin and Dar-Ming Lai. IgG4-related intracranial hypertrophic...